Anavex Life Sciences is a biotechnology business based in the US. Anavex Life Sciences shares (AVXL) are listed on the NASDAQ and all prices are listed in US Dollars. Anavex Life Sciences employs 38 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $6.80 |
|---|---|
| 52-week range | $6.75 - $15.24 |
| 50-day moving average | $8.06 |
| 200-day moving average | $8.87 |
| Wall St. target price | $47.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.64 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.8 from 2023-09-26
| 1 week (2023-09-20) | -6.08% |
|---|---|
| 1 month (2023-08-25) | -15.42% |
| 3 months (2023-06-27) | -15.84% |
| 6 months (2023-03-27) | -20.09% |
| 1 year (2022-09-27) | -26.49% |
|---|---|
| 2 years (2021-09-23) | N/A |
| 3 years (2020-09-25) | 75.71% |
| 5 years (2018-09-27) | 134.48% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -21.75% |
| Return on equity TTM | -34.72% |
| Profit margin | 0% |
| Book value | $1.80 |
| Market Capitalization | $564.6 million |
TTM: trailing 12 months
We're not expecting Anavex Life Sciences to pay a dividend over the next 12 months.
Anavex Life Sciences's shares were split on a 1:4 basis on 6 October 2015. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anavex Life Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Anavex Life Sciences shares which in turn could have impacted Anavex Life Sciences's share price.
Over the last 12 months, Anavex Life Sciences's shares have ranged in value from as little as $6.7499 up to $15.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anavex Life Sciences's is 0.6836. This would suggest that Anavex Life Sciences's shares are less volatile than average (for this exchange).
Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. .
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.